VE-PTP小分子抑制剂AKB-9778激活Schlemm管Tie2增加房水外流并降低眼压
本研究评估Tie2激活剂AKB-9778对眼压和房水外流功能的影响,在人类、兔和小鼠中检测其降眼压效果。AKB-9778皮下治疗糖尿病眼病患者可降低眼压,兔眼局部给药呈剂量依赖性降眼压,小鼠局部给药增加Schlemm管Tie2活化、降低眼压并增加房水外流易度。机制上AKB-9778增加Schlemm管滤过面积,支持其作为青光眼潜在新疗法。
要点
- AKB-9778皮下治疗糖尿病眼病患者可降低眼压。
- 兔眼局部AKB-9778呈剂量依赖性降低眼压。
- 小鼠局部AKB-9778增加Schlemm管Tie2活化并增加房水外流易度。
核心结论
- AKB-9778是首个在人类中显示降眼压作用的Tie2激活剂。
- AKB-9778通过重塑Schlemm管增加房水外流易度并降低眼压。
研究设计与样本
- 在人类、兔和小鼠中评估AKB-9778对眼压的影响。
- 在人和小鼠眼中定位VE-PTP。
- 在小鼠中监测AKB-9778对外流易度、Tie2磷酸化和Schlemm管滤过面积的影响。
主要发现
- AKB-9778皮下治疗糖尿病眼病患者可降低眼压。
- 兔眼局部AKB-9778呈剂量依赖性降低眼压。
- 小鼠局部AKB-9778增加Schlemm管内皮Tie2活化、降低眼压并增加房水外流易度。
- VE-PTP定位于人和小鼠眼的Schlemm管内皮细胞。
- AKB-9778在野生型和Tie2+/-小鼠中均增加Schlemm管房水外流滤过面积。
临床怎么用
- 局部眼用AKB-9778作为首创新Tie2激活剂,正在开展II期临床试验用于高眼压和青光眼治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (Tie2) activation in Schlemm's canal (SC) endothelium is required for the maintenance of IOP, making the angiopoietin/Tie2 pathway a target for new and potentially disease modifying glaucoma therapies. The goal of the present study was to examine the effects of a Tie2 activator, AKB-9778, on IOP and outflow function. METHODS: AKB-9778 effects on IOP was evaluated in humans, rabbits, and mice. Localization studies of vascular endothelial protein tyrosine phosphatase (VE-PTP), the target of AKB-9778 and a negative regulator of Tie2, were performed in human and mouse eyes. Mechanistic studies were carried out in mice, monitoring AKB-9778 effects on outflow facility, Tie2 phosphorylation, and filtration area of SC. RESULTS: AKB-9778 lowered IOP in patients treated subcutaneously for diabetic eye disease. In addition to efficacious, dose-dependent IOP lowering in rabbit eyes, topical ocular AKB-9778 increased Tie2 activation in SC endothelium, reduced IOP, and increased outflow facility in mouse eyes. VE-PTP was localized to SC endothelial cells in human and mouse eyes. Mechanistically, AKB-9778 increased the filtration area of SC for aqueous humor efflux in both wild type and in Tie2+/- mice. CONCLUSIONS: This is the first report of IOP lowering in humans with a Tie2 activator and functional demonstration of its action in remodeling SC to increase outflow facility and lower IOP in fully developed mice. Based on these studies, a phase II clinical trial is in progress to advance topical ocular AKB-9778 as a first in class, Tie2 activator for treatment for ocular hypertension and glaucoma.
引用
- Li G, Nottebaum AF, Brigell M, et al. A Small Molecule Inhibitor of VE-PTP Activates Tie2 in Schlemm's Canal Increasing Outflow Facility and Reducing Intraocular Pressure. Invest Ophthalmol Vis Sci. 2020. PMID: 33315051. doi:10.1167/iovs.61.14.12
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。